Panels to discuss Andexxa’s full approval, medical devices that use generative AI, and the REMS for clozapine

The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff

German pharma aiming to plug revenue hole as Xarelto nears patent cliff

Analysis of Eliquis, Xarelto spotlights complexities of Inflation Reduction Act

A rare Alexion deal for a marketed product comes at a relative discount as Portola’s stock price has sunk